Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
| Website | http://www.pluri-biotech.com |
| Employees | 248 (0 on RocketReach) |
| Founded | 2003 |
| Phone | +972 74-710-8600 |
| Industry | Biotechnology Research |
| Keywords | Cell Therapies, Biotechnology, Biotech Innovation, Life Sciences, Regenerative Medicine, Biomedical Engineering, Advanced Therapies, Bioprocessing, Stem Cell Technology, Cell Culture, Patented Technology, Biomanufacturing, Pharmaceutical Manufacturing, Precision Medicine, Therapeutic Solutions, Tissue Engineering, Drug Development, Scientific Research |
| Competitors | 10x Genomics, Illumina, Beckman Coulter Life Sciences, Thermo Fisher Scientific, Celsee, Inc., Parse Biosciences, NanoString Technologies, Inc., MilliporeSigma, Promega Corporation, Agilent Technologies +36 more (view full list) |
Looking for a particular Pluri employee's phone or email?